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1 Summary 
 
Canine mammary neoplasms are amongst the most common neoplastic diseases. It 
is assumed that reproductive hormones have an effect on tumoriogenesis, however, 
the precise role of the endocrine milieu and reproductive state is subject of continuing 
discussion. Therefore, this study investigated the association between circulating 
serum concentrations of estradiol-17, progesterone and prolactin (PRL), and gene 
expression of estrogen receptor , progesterone receptor, prolactin receptor (PRLR) 
and growth hormone receptor, with respect to reproductive state (spayed vs. intact) 
and cycle stage (anestrus vs. diestrus). Furthermore, as a possible indicator of 
metastatic potential we evaluated the expression of E-cadherin (CDH-1), which 
regulates cell-cell adhesion.  
The transformation from a normal to a malignant phenotype was associated with a 
significant loss of the gene receptor expression in the canine mammary tissue. Only 
PRLR in malignant tumors was significantly influenced by circulating PRL. Increased 
PRL levels were negatively associated with low PRLR gene expression in malignant 
tumors. No evidence was found for the presence of a paracrine/autocrine action of 
PRL in the canine mammary gland. 
For CDH-1, the highest gene expression was found in benign mammary tumors in 
diestrous dogs compared to normal and malignant mammary tissues of anestrous 
and spayed dogs. Therefore it may serve as a prognostic marker. 
 
Dog, mammary neoplasm, sex hormones, hormone receptors  
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2 Zusammenfassung 
 
Titel: 
 
Endokrinologische Kontrolle der Mamatumoren beim Hund: Serumwerte der 
Reproduktionshormone und Gewebsexpression von Steroidhormon-, 
Prolaktin- und Wachstumshormonrezeptoren 
 
Mammatumore sind die häufigsten Neoplasien der Hündin. Reproduktionshormone 
scheinen ihre Entstehung zu beeinflussen, der zugrunde liegende 
Pathomechanismus ist bisher nicht geklärt. Daher wurden die Zusammenhänge 
zwischen den Serumkonzentrationen von Östradiol-17, Progesteron und Prolaktin 
und den Genexpressionen von Östrogenrezeptor α, Progesteron-, Prolaktin- und 
Wachstumshormonrezeptor unter Berücksichtigung des Einflusses von 
Reproduktionsstatus und Zyklusstatus untersucht. Zusätzlich wurde E-Cadherin, ein 
Adhäsionsprotein, als möglicher Indikator für das Metastasierungsrisiko untersucht. 
Der Verlust der Rezeptorgenexpression war assoziiert mit der Transformation vom 
normalen zum malignen Phänotyp. Während die Steroidhormone die 
Genrezeptorexpression nicht beeinflussten, war die Genexpression des 
Prolaktinrezeptors in malignen Tumoren negativ mit dem Prolaktinblutspiegel 
assoziiert. Ein auto- oder parakriner Effekt von Prolaktin konnte im Mammagewebe 
nicht festgestellt werden. 
Die höchste E-Cadherin-Genexpression wurde in gutartigen Mammatumoren bei 
diöstrischen Hunden festgestellt; anöstrische und kastrierte Hunde hatten in 
normalem Mammagewebe oder in malignen Mammatumoren deutlich niedrigere 
Werte. Daher könnte die E-Cadherin-Genexpression als prognostischer Marker in 
Mammatumoren fungieren. 
 
Hund, Mammaneoplasie, Sexualhormone, Hormonrezeptor 
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4 Abstract 
Background:  
Neoplasms of the mammary gland are among the most common diseases in female 
domestic dogs (Canis familiaris). It is assumed that reproductive hormones influence 
tumorigenesis in this species, although the precise role of the endocrine milieu and 
reproductive state is subject to continuing discussion. In line with this, a recent 
systematic review of available data on the development of mammary neoplasms 
revealed weak evidence for risk reduction after neutering and an effect of age at 
neutering. Investigation of several hormone receptors has revealed decreased 
expression of estrogen receptor-alpha (ERα, ESR1), progesterone receptor (PGR), 
prolactin receptor (PRLR) and growth hormone receptor (GHR) associated with 
neoplastic differentiation of mammary tissues. In other studies, increased levels of 
estrogens, progesterone and prolactin were found in serum and/or tissue 
homogenates of dogs with malignant neoplasms. However, the association between 
these entities within one animal population was never previously examined. 
Therefore, this study investigated the association between circulating serum 
concentrations of estradiol-17β, progesterone and prolactin, and gene expression of 
ERα (ESR1), ERβ (ESR2), PGR, PRLR, PRL and GHR, with respect to reproductive 
state (spayed vs. intact) and cycle stage (anestrus vs. diestrus). Additionally, the 
expression of E-cadherin (CDH-1) was evaluated as a possible indicator of 
metastatic potential. 
 
Results:  
For all receptors, the lowest gene expression was found in malignant tumors 
compared to normal tissues of affected dogs. Steroid levels were not influenced by 
their corresponding receptor expression in mammary neoplasms, but increased PRL 
levels were negatively associated with low PRLR gene expression in malignant 
tumors. The expression of CDH-1 was influenced by tumor malignancy and cycle 
stage, i.e., the highest gene expression was found in benign mammary tumors in 
diestrous dogs compared to normal and malignant mammary tissues of anestrous 
and spayed dogs. 
 
Conclusions:  
Herein, it has been confirmed that transformation towards malignant neoplasms is 
associated with significant reduction of gene expression of particular hormone 
receptors. Only PRLR in malignant tumors seems to be influenced by circulating PRL 
levels. In dogs, CDH-1 can be used as a prognostic factor; its expression, however, 
in benign tumors is influenced by cycle stage. 
 
Keywords: Dog, mammary neoplasm, sex hormones, hormone receptors.  
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5 Background 
Estrogens (estradiol 17; E2), progesterone (P4), prolactin (PRL) and growth 
hormone (GH) are essential for physiological mammary growth and development, 
which not only take place during pregnancy but also occur with every reproductive 
cycle. While estrogens induce ductal growth, P4 is essential together with PRL for 
lengthening and tertiary branching of the ductal system and stimulation of lobulo-
alveolar development [1, 2]. Furthermore, PRL promotes changes of the alveolar 
cells towards a secretory type and induces lactation [1-4]. The effects of these 
hormones are mediated through binding to their respective receptors within the 
mammary gland. Changes in the expression of E2, P4 and GH receptors (ER, PGR 
and GHR, respectively) but not of prolactin receptors (PRLR) have been described in 
normal canine mammary tissue during different phases of the estrous cycle [5-8]. In 
addition to physiological changes in the mammary gland during the estrous cycle, 
different pathological changes may occur. Tumors are considered to be the most 
common disorders of the mammary gland in dogs. Reproductive state and the 
endocrine milieu seem to play a pivotal role in the development of canine mammary 
tumors (CMT). The sparing effect of early spaying on CMT formation has been 
known since the work of Schneider and colleagues in 1969 [9]. However, a recent 
systematic review of peer-reviewed journal articles concluded that the evidence for a 
reduced CMT risk following ovariohysterectomy, as well as for an influence of age at 
neutering, is weak [10]. Studies investigating the impact of spaying, performed 
concurrently or shortly before the time of mammary tumor surgery, on disease-free 
interval or survival time yielded inconsistent results, showing either a beneficial effect 
of ovariohysterectomy or no effect [11-15]. Yet, a role for E2 in mammary 
tumorigenesis was suggested by its higher blood levels in dogs with malignant 
neoplasms compared to those without tumors [16-18]. On the other hand, bitches 
with inflammatory mammary carcinoma had lower estrogen levels compared to 
animals with other carcinoma subtypes [16]. An involvement of P4 in mammary 
tumorigenesis was also suggested, because treatment with progestins increased the 
risk of CMT [19-21], which is probably due to up-regulation of local GH production 
within the gland [22]. However, no significant differences in endogenously derived P4 
serum concentrations were found between bitches with and without mammary 
neoplasms [17, 18]. A tumorigenic effect of PRL on the mammary tissue was 
hypothesized, because dogs with CMT had higher PRL levels than healthy animals 
[17, 23]. 
 
Despite the presumed influence of reproductive hormones, studies on endocrine 
therapy for CMT are rare. Gene or protein expression of ERα (ESR1) and/or ERβ 
(ESR2), PGR, PRLR and GHR were detected in CMTs, and decreased receptor 
expression was associated with malignancy and/or a worse prognosis [8, 16, 24-32]. 
Nevertheless, the application of a PGR blocker decreased PGR expression in canine 
mammary carcinoma cells and reduced cell proliferation in vivo and cell viability in 
vitro [33, 34]. The selective ER modulator tamoxifen, which is part of the standard 
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therapy for women with ER-positive breast cancer [35-37], is not recommended in 
dogs due to its partial agonistic potential and the associated side effects [38, 39]. 
Lowering PRL serum levels by oral application of the dopamine receptor agonist 
cabergoline reduced the size of certain mammary lesions in 25 % of clinically 
pseudopregnant dogs presenting with mammary tumors [40]. 
 
Markers of tumor invasion are used in human medicine to estimate survival time and 
prognosis [41]. E-cadherin, the product of the CDH-1 gene, is expressed on the 
surface of most epithelial cells and regulates cell-cell adhesion. In women, loss or 
down-regulation of CDH-1 in breast carcinoma is associated with shorter survival 
time [42-44]. Similarly, in dogs, reduced immunostaining for CDH-1 is correlated with 
increased invasion potential, lymph node metastasis, histological grade and 
infiltration [45-48]. 
 
Mastectomy is regarded as the most effective treatment for CMT so far. However, 
further therapeutic options should be sought, which could be used in combination 
with surgery or in cases of non-operable lesions and inflammatory mammary 
carcinomas. Knowledge of the interplay between hormones and their receptors 
during the reproductive cycle, after spaying or during tumorigenesis, could provide a 
basis for new and advanced therapeutic approaches for dogs with CMT. 
 
Up to now, there is no information on the effect of serum steroid hormone and PRL 
levels on their respective receptor gene expression in normal and neoplastic 
mammary tissues in dogs. Our goal was, therefore, to study the associations 
between circulating serum concentrations of E2, P4 and PRL, and the expression of 
genes encoding for their respective receptors, i.e., ERα (ESR1), ERβ (ESR2), PGR, 
PRLR, PRL, as well as GHR, in normal mammary tissues as well as in mammary 
neoplasms in female dogs, taking into account their reproductive state and cycle 
stage. Furthermore, gene expression of CDH-1 was analyzed as a marker for tumor 
invasiveness in mammary tissues showing different degrees of malignancy. In 
addition, the influence of reproductive state and cycle stages were assessed for all 
parameters. 
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6 Methods 
6.1 Animals, tissues 
A prospective study was carried out with 32 privately owned female dogs that were 
presented with mammary neoplasms to the Clinic of Reproductive Medicine, 
Vetsuisse Faculty in Zurich between 2009 and 2013. Altogether, 56 mammary 
neoplasms and 28 normal mammary tissue samples were collected from these 
patients. Eleven dogs had only one mammary neoplasm and 21 bitches had two or 
more lesions. Mastectomy was performed in 28 dogs to remove the masses. The 
following surgery techniques were used: unilateral mastectomy (n = 12), unilateral 
mastectomy combined with regional mastectomy (n = 3), regional mastectomy 
(n = 11), excisional biopsy (n = 2). Three of four dogs with inoperable cancer were 
euthanized at initial presentation because of their poor general condition. The fourth 
dog was euthanized two months later because of severe dyspnea due to pulmonary 
metastasis.  
 
The phase of the estrous cycle at presentation was determined based on history, 
clinical examination and blood hormone assays (P4 and E2). 
 
All owners consented to their animal becoming a research participant and animal 
experimentation was approved by the Cantonal Veterinary Authority in Zurich, 
Switzerland (permission No. 136/2009 and 165/2012).  
6.2 Blood sampling and hormone analysis  
In order to account for the possible pulsatile release and circadian rhythm of PRL 
secretion [49, 50], two blood samples were collected 30 min apart and always in the 
morning from each dog prior to surgery or before euthanasia. Samples were 
centrifuged after clotting, and serum was stored at −20 C until hormone analysis. 
 
Serum PRL concentrations were measured with a previously validated heterologous 
radioimmunoassay (RIA) [51]. The intra-assay coefficient of variation was 3.5 %, and 
the lower limit of detection was 0.8 ng/ml. All serum samples were analyzed in the 
same run. The mean of the two PRL concentrations from each dog was used for 
statistical analysis. 
 
E2 and P4 were determined from the first serum sample. E2 concentrations were 
determined by a solid-phase 125I-RIA (Count-A-Count TKE; Siemens Medical 
Solution Diagnostics, Los Angeles, CA, USA) according to the manufacturer’s 
instructions, with slight modifications as described previously and validated for the 
dog [52, 53]. The intra-assay coefficient of variation was 14 %, and the lower limit of 
detection was 1.9 pg/ml. Serum P4 concentrations were measured with a previously 
validated 3H-RIA [51, 54]. The intra- and inter-assay coefficients of variation were 11 
and 9.7 %, respectively, and the lower limit of detection was 0.04 ng/ml. 
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6.3 Tissue collection, histopathological classification and sample 
processing 
Neoplastic and normal mammary tissue samples from each dog were collected by 
surgical mastectomy, biopsy or immediately post mortem. Tissue samples were fixed 
in 10 % buffered formalin for 24 h and embedded in paraffin. Sections from each 
block were stained with hematoxylin and eosin (HE) for histopathological diagnosis 
according to the criteria of Goldschmidt [55], and then grouped as normal mammary 
tissue, or benign or malignant mammary neoplasms. 
 
The experimental procedure was based on our previously established protocol [25]. 
Thus, on the HE stained slides, representative parts of mammary neoplasms and 
normal mammary tissue from each dog were identified and marked. These parts 
were identified in the original paraffin blocks, cut out manually and re-embedded 
separately in paraffin. Consecutive sections from these new paraffin blocks were cut 
using a rotary microtome (RM 2165, Leica, Wetzlar, Germany). The first section (3 
μm thick) was used for control HE staining, the following sections (10 μm thick) for 
RNA extraction (see below), and the last section (3 μm thick) for another control HE 
staining. The number of sections cut for RNA extraction varied from 15 to 30 
depending on neoplasm size. The first and last control HE sections were compared 
to the selected representative part of the mammary tissue sample. If the control 
slides did not match the selected tissue, the original paraffin block was re-sampled 
and re-embedded as described above until both control slides matched the selected 
area. 
6.4 RNA extraction and semi-quantitative real-time (TaqMan) PCR 
Excess paraffin was manually removed from each representative tissue section in a 
warm water bath (37°C), and all sections were transferred into a 1.5 ml plastic 
Eppendorf tube (Eppendorf, Hamburg, Germany). Total RNA was extracted using the 
RNeasy FFPE Kit (Qiagen, Hombrechtikon, Switzerland) according to the 
manufacturer’s instructions. The RNA concentration was measured with a NanoDrop 
2000 UV–vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The 
RNA quality was assessed by checking the RNA integrity numbers (RIN) and 
samples with similar RIN were used for all groups. Extracted RNA was stored at 
−80°C until analysis. 
 
In order to remove genomic DNA contamination, 50 ng RNA per reaction was DNase 
treated (RQ1 RNase-free DNase, Promega, Dübendorf, Switzerland) in accordance 
with the manufacturer’s instructions. Afterwards, RNA was reverse transcribed into 
complementary DNA (cDNA) using Sensiscript ™ Reverse Transcriptase (Qiagen) 
and random hexamers (Applied Biosystems, Foster City, CA, USA) as primers 
according to the manufacturer’s instructions. All reactions were carried out in an 
Eppendorf Mastercycler (Vaudaux-Eppendorf AG, Basel, Switzerland). 
 
Semi-quantitative real-time (TaqMan) PCR reactions for ERα (ESR1), ERβ (ESR2), 
PGR, PRL, PRLR, GHR and CDH-1 were performed as described previously [56, 57] 
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using three independent endogenous reference genes (canine GAPDH, 18SrRNA 
and cyclophilin A) in the comparative CT method (ΔΔCT method). Samples were run 
in duplicates on a 96-well optical plate using an automated fluorometer ABI 7500 
Fast Real Time PCR System (Applied Biosystems). Per reaction, 6.25 μl Fast Start 
Universal Probe Master (ROX) (Roche Diagnostics, Rotkreuz, Switzerland), 300 nM 
of each primer, 200 nM TaqMan probe, 1.75 μl autoclaved water, and 2.5 μl of 50 ng 
RNA were used as the TaqMan PCR reaction mixture. Amplification was performed 
by denaturation for 10 min at 95°C, 40 cycles at 95°C for 15 sec and 60 sec at 60 C. 
Autoclaved water and the RT minus control were used as negative controls. The 
sequences of the primers and the 6-carboxyfluorescein (6-FAM) and 6-
carboxytetramethyl-rhodamine (TAMRA) labeled TaqMan probes were designed 
using Primer Express Software (Version 2.0, Applied Biosystems) and are listed in 
Table 1. All primers and probes were purchased from Microsynth (Microsynth AG, 
Balgach, Switzerland). The canine–specific TaqMan Gene Expression Assay of 
Cyclophilin A (Prod. No. Cf03986523-gH), GHR (Prod No. Cf02623459_m1) and 
CDH-1 (Prod. No. Cf02624268_m1) were purchased from Applied Biosystems. The 
specificity of selected PCR products for each gene was confirmed by commercial 
sequencing (Microsynth). 
6.5 Statistical analysis 
Raw data are presented as the mean and standard deviation (SD). A t-test was 
performed to compare serum hormone levels of dogs in different reproductive states 
and cycle stages. The statistical software “R” version 3.0.2 [58] and the package 
“nlme” [59] were used for the analysis of different statistical models with receptor 
gene expression as the outcome variable. Due to the repeated measurements per 
animal, linear mixed-effects models were applied. Animal was taken as a random 
effect. For the analysis of receptor gene expression in mammary tissue, outcome 
variables of PRLR, PGR, ERα (ESR1) and ERβ (ESR2) were used with the following 
predictor variables in the models: corresponding hormones of PRL, P4, E2; tissue 
group with the categories normal, benign, malignant; reproductive state and/or cycle 
with the categories spayed, anestrous, diestrous. Additionally, interactions between 
tissue group and hormone levels were evaluated. For the outcome variables GHR 
and CDH-1, the following predictor variables were tested: tissue group (normal, 
benign, malignant), reproductive state and/or cycle stage (spayed, anestrous, 
diestrous). For GHR and CDH-1, interactions between tissue group and reproductive 
state and/or cycle stage were also analyzed. Model selection was based on the 
Akaike information criterion (AIC) with lower values indicating a better model fit. A 
difference of at least −2 was considered as indicative of a better model fit. If AIC 
values differed by less than 2, the model with the lowest number of predictors was 
chosen (principle of parsimony). Results of the linear mixed effect models are given 
as p-values and effect size with their standard errors (SE). A p < 0.05 was considered 
significant. 
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7 Results 
7.1 Animals and neoplasm classification 
The ages of dogs at the time of blood and tissue sampling ranged from 4.6 to 16.4 
years (mean ± SD, 9.8 ± 2.69). Bitches were of different breeds, the most frequent 
being mixed breed dogs (n = 9), Jack Russell terriers (n = 3), Boxers (n = 2) and 
dachshunds (n = 2). 
 
Twenty-four bitches were intact, of which 13 were in anestrus and 11 in diestrus. 
Eight dogs had been previously spayed before the time of mastectomy, six between 
the ages of 7 and 10 years, one before 18 months of age, and in one dog no 
information was available. 
 
The group of benign mammary neoplasms consisted of 19 tissue samples out of 12 
dogs, the malignant neoplasia group of 37 samples from 24 dogs. Benign neoplasms 
included complex adenomas (n = 10), simple adenomas (n = 6), mixed benign 
mammary tumors (n = 2) and one ductal adenoma. The malignant group consisted of 
complex carcinomas (n = 14), simple carcinomas (n = 12), anaplastic carcinomas 
(n = 3), solid carcinomas (n = 3), ductal carcinomas (n = 3), one adeno-squamous 
carcinoma, and one carcinoma and malignant myoepithelioma. Normal tissue was 
available from 28 dogs. 
7.2 Hormonal analysis and gene expression 
Serum levels of E2, P4 and PRL varied between 0.52 and 16.32 pg/ml, 0.05 and 91.4 
ng/ml, and 1.32 and 8.91 ng/ml, respectively (Table 2). Serum for E2 measurement 
was not available from two dogs that were both affected by simple adenomas. 
 
Gene expression of ERα (ESR1), PGR, PRLR, GHR and CDH-1 was detected in 
normal mammary tissues and in all mammary neoplasms, except in one carcinoma. 
The PRL and ERβ (ESR2) mRNA expression was below the detection limit in most of 
the samples in all groups, revealing more negative than positive results and, thereby, 
indicating their low expression levels. Corpus luteum tissue (mid-diestrus) used as a 
positive control tested positively for both factors (Additional File 1 (1.2)). 
 
Regarding gene expression of reproductive hormone receptors, the best predictor 
variable tested was “tissue group” for ERα (ESR1) (p = 0.03), PGR (p = 0.008) and 
PRLR (p = 0.001). Thus, malignant tumors showed significantly lower ERα (ESR1) 
and PGR gene expression than normal mammary tissues (p = 0.017 and p = 0.002, 
respectively; Fig. 1A and B). PRLR mRNA expression was significantly lower in both 
benign and malignant mammary neoplasms than in normal tissues (p = 0.009 and 
p < 0.001, respectively) with lowest values detected in the malignant group (Fig. 1C). 
 
Out of the models containing “hormone blood level” and “tissue group” a relationship 
was only found for PRLR mRNA expression: PRL blood levels had a negative 
relationship with PRLR gene expression only in malignant neoplasms (p = 0.025). In 
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contrast to these finding, the corresponding models for PGR and ERα (ESR1) did not 
show a relationship with their hormone levels (p = 0.07 and p = 0.11, respectively). 
 
GHR gene expression was also predicted best by “tissue group” (p = 0.008). 
Consequently, GHR mRNA levels were significantly lower in malignant neoplasms 
compared to normal mammary tissue (p = 0.003; Fig. 1D). 
 
In all other models, i.e., those using the predictors variable blood level, reproductive 
state and/or cycle stage, as well as the interaction between tissue group and 
reproductive state/cycle stage variables, were not significantly associated with 
receptor expression. 
 
In contrast to the expressions of reproductive hormone receptors, the gene 
expression for CDH-1 revealed a significant interaction (p = 0.012) for both “tissue 
group and reproductive state and/or cycle stage”. Among diestrous bitches, CDH-1 
gene expression was highest in benign neoplasms compared to normal mammary 
tissue and malignant neoplasms (p = 0.001 and p = 0.008, respectively; Fig. 1E). 
However, no such differences were found between samples collected in other 
reproductive states or cycle stages, either in spayed animals (p = 0.63 and p = 0.89, 
respectively) or in anestrous dogs (p = 0.09 and p = 0.09, respectively). Analyzing 
mammary samples according to “tissue group”, benign neoplasms from diestrous 
bitches expressed significantly higher levels of CDH-1 mRNA than benign neoplasms 
from spayed or anestrous dogs (p = 0.003 and p = 0.026, respectively; Fig. 1 F). 
CDH-1 gene expression in malignant neoplasms and in normal mammary tissue was 
similar between diestrous and spayed (p ≥ 0.23), and between diestrous and 
anestrous dogs (p ≥ 0.33). The AIC values of models, which tested the relationship 
between the expression of CDH-1 and E2, P4, or PRL levels were higher than those 
determined for the model describing the expression of CDH-1 gene in dependence of 
tissue group and reproductive status/cycle stage. Thus, hormone levels had no 
influence on CDH-1 expression in our study. 
 
Detailed information on hormone levels, reproductive states and cycle stages, and 
relative gene expression of receptors detected in normal tissues and/or mammary 
tumors per dog are presented in the Additional File 1 (1.1).   
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8 Discussion 
Growth of mammary epithelial cells is stimulated by steroid hormones [60, 61], PRL 
[62] and GH [7]. In dogs, most studies showed lower ERα (ESR1) as well as PGR 
expression in malignant compared to benign mammary tumors [29, 31, 63] or normal 
mammary tissue [16, 29, 30]. A tendency for decreased GHR expression was also 
noted, particularly in undifferentiated carcinomas [7, 8], which showed 
heterogeneous immunoreactivity compared to diffuse staining in normal tissue and 
benign tumors [8]. These studies are in accordance with our findings of decreased 
mRNA expression of ERα and PGR in malignant CMTs compared to normal tissue, 
although benign neoplasms were not different in these respects from either malignant 
or normal samples. The loss of or decreased receptor expression may be indicative 
of increasing resistance to hormonal stimulatory effects [64], and might serve as an 
indicator of malignancy as suggested before [8, 16, 29-31, 63].  
 
The possible influence of steroid hormone levels on mammary tumors in dogs was 
previously investigated [16-18]. Thus, higher E2 concentrations were found both in 
serum as well as in tissue homogenates in cases of non-inflammatory malignant 
neoplasms compared to normal mammary tissue [16-18] or to benign tumors [17]. P4 
levels showed a similar trend but only in tissue homogenates [18]. In contrast to 
these previous studies, which included only intact dogs in anestrus [16-18], our 
animal population represented different reproductive states and cycle stages 
including diestrous dogs, and various types of mammary tissue samples to take into 
account the multicentric nature and diversity of CMTs [65]. This approach may 
include possible effects of a malignant neoplasm on the remaining mammary gland, 
i.e., altering its gene expression levels or influencing sex steroid and PRL serum 
levels. However, to gather sufficient information, a much larger data base would be 
required. Furthermore, to investigate the postulated tumor-promoting effects of sex 
hormones during early carcinogenesis, longitudinal data would be desirable. 
 
All of the above-cited studies evaluated either expression patterns of the respective 
hormone receptors, or the hormonal status of diseased dogs, and/or the local 
hormonal status of tumors. However, the association between these entities within 
one animal population has never been studied before. Consequently, the present 
study was initiated to establish such possible relationships. Based on the results 
presented herein, we infer that neoplasm type is the primary determinant of canine 
mammary steroid hormone receptor gene expression while other factors, including 
circulating steroid hormone serum concentrations, reproductive state and cycle 
stage, as well as interactions among the above, seem to have little or no influence. 
This is not surprising, because most dogs affected by mammary cancer have multiple 
lesions of different histological types [55, 66, 67]. Therefore, we intentionally included 
more than one neoplasm per dog when several lesions were present, and took the 
animal as a random factor into account in the statistical analyses as this best 
represented the affected dog population. 
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Considering the lack of the effect of the reproductive status and/or cycle stage, and 
thereby, of the hormonal status on the respective hormone receptor expression, this 
could be due to the physiological high variation of hormonal levels in dogs, 
overlapping with the limited number of samples used for our study, and the possible 
breed effects. 
 
The PRL-PRLR complex plays a role in mammary tumorigenesis, as shown, e.g., in 
human breast cancer [68]. In agreement with our previous study [25], we detected 
decreasing PRLR gene expression levels during the course of malignant 
transformation, i.e., from normal mammary tissue towards benign and further to 
malignant transformation [25]. However, in that previous study, the reproductive state 
of the dogs was unknown, serum hormone levels were not investigated and CMTs 
consisted of a more homogeneous group of adenomas and adenocarcinomas. In the 
present study, we found increased serum PRL levels in malignant CMTs, which were 
associated with low PRLR gene expression. Similarly, high PRL concentrations in 
serum and tissue homogenates were previously shown in dogs suffering from 
malignant tumors [17, 23]. One possible explanation for these findings is that high 
levels of PRL induced down-regulation of PRLR transcription in the mammary gland. 
This could be a sign of loss of differentiation in the neoplastic cells, in which case 
PRL would have little or no effect in these malignant neoplasms. PRL is known to 
modulate the availability of its own receptor by stimulating its proteolytic degradation. 
This impaired PRLR turnover, which leads to its stabilization and accumulation, 
presumably increases the magnitude and duration of PRL signaling and contributes 
to transformation of human mammary epithelial cells [69, 70].  
 
As indicated above, in dogs as in humans, PRL can be produced not only in the 
anterior pituitary, but also in normal mammary tissue and malignant mammary 
tumors [17, 23, 71-73]. Moreover, higher tissue PRL levels were observed by 
Queiroga and colleagues in CMT homogenates [17, 23]. Consequently, the 
autocrine/paracrine loop of mammary PRL-PRLR complex [71-73] contributing to 
human breast cancer development [74] has also been implied for the dog [17, 75]. 
Contrasting with these previous findings, in the present study the local expression of 
PRL mRNA was below detection limits in the canine mammary gland. However, 
mRNA concentrations might not always reflect the actual PRL concentrations at the 
protein level. 
 
The activation of PRLR by PRL results in signaling through the Jak2/Stat5a pathway. 
Stat5 activation initiates cell differentiation through expression of the CDH-1-β-
catenin complex [76, 77], which may suggest a protective effect of PRL against 
neoplasm formation, because decreased Stat5a activation was associated with 
metastatic progression in human breast cancer [78]. At present, it is still not clear 
whether PRL acts as a promoter or a suppressor of neoplasm development or as a 
promoter of differentiation [79-82]. Nevertheless, reduced immunohistochemical 
expression of CDH-1 in the mammary gland was related to malignancy, invasive 
growth, lymph node metastasis, necrosis, differentiation grade, size and ulceration of 
the tumor in dogs [45-48, 83]. There is limited knowledge on the molecular 
mechanisms behind CDH-1 down-regulation in CMTs, and about when it occurs 
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during neoplastic progression. Pardini and colleagues [84] showed decreased CDH-1 
mRNA expression in dogs with mammary carcinoma compared to normal tissue. We 
could not confirm this finding, as in our study similar mRNA concentrations were 
detected in normal mammary tissue and in malignant neoplasms. However, 
modifications in post-translational N-glycosylation of CDH-1 [85] cannot be ruled out, 
which may result in decreased cell-cell adhesion in the malignant lesions. 
Interestingly, we found increased CDH-1 gene expression in benign compared to 
malignant neoplasms, which supports the role of CDH-1 as a marker for cell 
differentiation. This is in line with the lack of metastatic and invasive properties of 
benign neoplasms. The highest CDH-1 mRNA levels were seen in benign lesions 
during the diestrus phase, which may be attributed to the effects of P4. Similarly, 
CDH-1 gene expression was up-regulated in the canine uterus under P4 treatment 
and during pregnancy [86]. In contrast to our expectations, reproductive state or 
cycle stage had no effect on CDH-1 mRNA levels in normal mammary tissue. This 
could be, however, due to the source of the normal/healthy tissue used for the 
present study, which was collected from dogs affected by mammary tumors. The 
microenvironment of malignant mammary tumor could have a modulatory effect on 
the expression of CHD-1. 
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9 Conclusion 
The transformation from a normal to a malignant phenotype was associated with a 
significant loss of ERα (ESR1), PGR, GHR and PRLR gene expression in the 
mammary tissue of dogs. Only PRLR gene expression was significantly decreased 
concurrently with the formation of benign tumors. Increased levels of serum PRL, but 
not of P4 and E2, were associated with a decrease in gene expression of the 
respective receptors only in malignant mammary neoplasms. No evidence was found 
for the presence of a paracrine/autocrine action of PRL in the canine mammary 
gland. CDH-1 mRNA expression was higher in benign compared to malignant 
neoplasms and normal mammary tissue and thus may serve as a prognostic marker. 
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12 Figures and tables 
12.1 Figure 1 
Model results of relative gene expression (fold changes in mRNA levels, mean 
± SE) of (A) ERα (ESR1), (B) PGR, (C) PRLR and (D) GHR in normal mammary 
tissue, benign and malignant neoplasms. The significant interaction for tissue 
group and reproductive state/cycle on CDH-1 gene expression is shown in 
(E,F); (E) Relative gene expression (fold changes in mRNA levels, mean ± SE) of 
CDH-1 in normal mammary tissue, benign and malignant mammary neoplasms of 
diestrous dogs; (F) Relative gene expression (fold changes in mRNA levels, mean ± 
SE) of CDH-1 in benign mammary neoplasms collected from spayed dogs, anestrous 
and diestrous bitches. Bars with different superscripts differ at p<0.05.  
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12.2 Table 1 
List of primers and TaqMan probes used for the semi-quantitative real-time 
(TaqMan) PCR. 
 
12.3 Table 2 
Serum E2, P4 and PRL concentrations in dogs with mammary neoplasms.  
Values are shown as mean ± SD. Same superscripts within a column denote 
significant differences at p<0.05 (assessed with a t-test). 
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13 Additional File 1 
13.1 Additional File 1.1 
Hormone levels, reproductive states, cycle stages, and relative gene 
expression (RGE) of receptors in normal tissues and/or mammary tumor(s) per 
dog. 
N/A: not available 
 
E2 P4 PRL
pg/ml ng/ml ng/ml PRLR PGR Erα GHR CDH-1 tumour typ ERα (ESR1) PGR PRLR GHR CDH-1
1 intact (diestrus) N/A 3.69 4.48 55.18 92.15 N/A 9.29 20.25 simple adenoma N/A 223.13 115.53 13.29 130.43
complex adenoma 30.84 72.45 90.51 9.54 53.01
complex adenoma 13.77 7.31 26.16 8.22 40.48
simple adenoma 46.58 173.17 114.53 8.56 72.17
complex adenoma 73.90 118.35 135.57 18.24 77.64
simple adenoma N/A 180.66 255.83 25.05 31.49
simple adenoma N/A 55.45 78.23 18.10 77.74
5 intact (anestrus) 9.46 1.13 3.20 99.99 128.35 239.54 125.79 73.77 complex adenoma 46.94 66.67 114.75 123.67 42.12
6 spayed 2.35 0.22 3.41 147.38 102.97 29.47 59.55 64.14 complex adenoma 297.08 88.35 108.75 56.16 32.59
simple adenoma 439.53 159.43 223.74 63.70 97.05
complex adenoma 296.24 38.42 130.94 80.08 56.70
mixed benign mammary tumor 109.35 16.78 51.47 51.71 37.29
8 intact (anestrus) 5.43 0.11 8.05 218.99 132.99 159.00 4.87 36.49 anaplastic carcinoma 31.67 30.71 8.14 5.38 18.85
complex carcinoma 14.74 29.33 17.95 27.24 14.55
complex carcinoma 6.69 42.30 24.36 10.40 40.12
simple carcinoma 19.57 7.79 21.07 8.12 7.43
complex carcinoma 3.71 8.90 22.41 11.31 45.92
11 intact (diestrus) 13.23 51.1 3.34 N/A N/A N/A N/A N/A simple carcinoma 116.18 146.50 110.45 72.13 56.73
simple carcinoma 146.58 19.12 184.20 27.68 67.45
complex carcinoma 40.10 163.79 148.59 29.70 44.10
complex carcinoma 99.91 126.03 87.04 14.72 27.28
13 intact (diestrus) 10.79 70.94 3.41 461.70 57.31 121.16 186.13 11.83 ductal carcinoma 29.17 62.16 77.73 34.09 28.99
simple carcinoma 53.70 20.39 7.93 12.40 30.66
adeno-squamous carcinoma 11.94 3.81 42.46 11.09 35.74
15 simple carcinoma 5.61 20.19 27.28 5.86 18.82
complex carcinoma 80.21 25.85 70.53 6.10 17.94
16 spayed 1.66 0.32 4.39 N/A N/A N/A N/A N/A anaplastic carcinoma 2.86 1.19 8.54 5.97 1.00
17 spayed 4.44 0.47 1.79 77.00 213.01 2.92 80.74 39.56 complex carcinoma 2.05 89.67 224.29 43.04 45.64
18 intact (anestrus) 3.26 1.34 2.81 N/A N/A N/A N/A N/A simple carcinoma 114.60 158.41 72.68 19.28 36.07
19 intact (anestrus) 6.40 0.08 8.23 282.40 159.01 189.22 28.69 56.43 anaplastic carcinoma 3.30 1.76 2.29 10.60 32.61
20 intact (anestrus) 8.66 0.44 2.77 197.63 148.29 80.62 12.62 37.79 simple carcinoma 79.30 129.57 72.95 7.81 82.83
21 simple carcinoma 65.46 181.29 79.54 34.28 101.04
simple carcinoma 20.20 72.64 35.11 13.53 18.90
22 intact (diestrus) 11.70 91.4 4.63 45.24 26.47 97.62 31.57 72.61 complex carcinoma 31.80 51.33 50.76 43.62 29.28
23 intact (diestrus) 9.02 5.54 4.22 93.39 197.14 49.06 54.77 47.68 complex carcinoma 523.39 91.15 104.05 19.75 36.46
24 intact (diestrus) 13.08 18.54 7.64 264.84 33.94 15.93 2.86 49.29 carcinoma and malignant myoepithelioma 7.36 63.58 29.02 8.84 33.55
complex adenoma 58.90 8.82 30.10 11.39 24.45
complex carcinoma 15.97 31.33 16.22 15.85 6.56
complex carcinoma 87.69 96.70 59.16 24.06 60.88
complex adenoma 109.78 3.33 65.00 63.99 108.02
simple carcinoma 73.82 147.30 61.95 39.11 148.07
ductal adenoma 6.68 24.91 5.47 7.80 85.92
ductal carcinoma 6.26 30.08 14.59 4.00 55.91
simple adenoma 114.20 24.81 100.59 57.66 103.97
simple carcinoma 96.58 57.61 47.66 12.58 79.87
complex carcinoma 2.28 12.36 31.10 2.59 34.70
solid carcinoma 4.43 10.21 4.35 4.61 31.87
simple carcinoma 9.87 7.05 32.80 8.86 15.29
complex carcinoma N/A 74.60 54.79 17.10 18.00
30 intact (diestrus) 13.87 24.53 4.06 123.14 21.35 69.03 27.40 24.57 ductal carcinoma 77.63 92.55 75.51 52.70 84.12
complex adenoma 111.66 196.15 193.50 76.61 37.47
complex adenoma 28.75 43.46 33.46 17.39 10.09
benigne mixed tumor 23.75 20.52 6.11 19.67 3.49
complex carcinoma 39.62 62.72 30.25 21.44 20.90
solid carcinoma NA 7.74 N/A 3.70 64.86
solid carcinoma 9.65 117.36 1.60 2.33 46.02
reproductive 
state/ cyclus 
normal mammary tissue per dog (RGE)dog
intact (anestrus) 76.95 33.08 53.47
mammary tumor(s) per dog (RGE)
intact (anestrus)
N/A 274.77 49.084.300.26
11.53 10.03 8.94
282.09 221.89N/A
79.51 10.78 123.29 3.03
intact (anestrus)
intact (anestrus)
spayed
spayed
intact (diestrus)
intact (anestrus)
spayed
intact (anestrus)
spayed
27
26
25 2.45 0.87
intact (anestrus)32
31
29
28
intact (diestrus)
intact (anestrus)
intact (diestrus)
intact (diestrus)
spayed
4.10 0.5 80.65 7.96 18.19
168.59 166.80 268.48 69.10 17.19
66.86 143.43 87.05 32.31 38.98
194.41 46.89 54.70 9.61 31.40
6.22
155.03 354.87
187.36 52.72
99.92 36.35
11.11 7.1 2.50
2.88 0.22 4.01
15.70 8.37 4.34
3.95
9.45 6.66 4.08
3.078.05 0.39 286.29 11.25 34.33
7
2
3
4
9
10
12
14
11.40 0.13 3.17 148.55 312.11
412.40 37.07 43.26
119.03 179.96 105.01 92.02 26.27
10.56
139.59 99.69 46.13
16.32 0.07 2.02 155.48 71.66 230.37 54.00 38.72
1.87 0.1 1.32 233.58 56.68
139.17140.192.780.715.91
49.01 14.26 18.95
22.9422.6273.65
67.534.27 0.67 2.04 124.34
29.39 40.23 60.72
N/AN/A
0.52 0.05 2.89 100.99 52.76
47.46 13.01 9.95
2.63 0.15 1.97 N/A N/A N/A
13.87 0.24 3.14 90.13 46.93
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13.2 Additional File 1.2 
Positive controls for luteal PRL and ERβ (ESR2) expression as determined by 
conventional RT-PCR. 
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